Press Releases

OccuLogix's Request to Transfer to NASDAQ Capital Market Approved
Jul 29, 2008

OccuLogix Secures Additional Bridge Loan
Jul 28, 2008

OccuLogix, Inc. Files Restatements of Financial Statements
Jul 21, 2008

OccuLogix, Inc. Announces Restatements of Financial Statements Relating to Consolidation of OcuSense, Inc.
Jun 18, 2008

OccuLogix Announces U.S.$5,076,500 Private Placement of Common Stock
May 20, 2008

OccuLogix Reports Q1-08 Financial Results
May 07, 2008

OccuLogix Secures Additional Bridge Loan
May 05, 2008

OccuLogix Enters Into Definitive Merger Agreement to Acquire 100% of OcuSense
Apr 22, 2008

OccuLogix' POC Diagnostics Subsidiary, OcuSense, Achieves ISO 13485:2003 Certification
Apr 08, 2008

OccuLogix' POC Diagnostics Subsidiary Achieves Final TearLab(TM) Osmolarity System Development Milestone and Progresses to Manufacturing Stage
Apr 04, 2008

OccuLogix Receives Going Concern Qualification
Mar 24, 2008

OccuLogix Receives Nasdaq Delisting Letter and Confirms Intention to Appeal
Mar 20, 2008

OccuLogix Reports 2007 Financial Results
Mar 17, 2008

OccuLogix Secures $3 Million Bridge Loan
Feb 19, 2008

OccuLogix Receives Letter From Nasdaq Regarding Non-Compliance With Minimum Market Value of Publicly Held Shares Rule
Feb 05, 2008

OccuLogix Provides Update
Jan 09, 2008

OccuLogix Sells SOLX Subsidiary
Dec 20, 2007

OccuLogix Reports Q3-07 Financial Results
Nov 09, 2007

OccuLogix Provides Update on Expected Timing of Q3-07 Results Release
Nov 07, 2007

OccuLogix Suspends RHEO(TM) System Clinical Development Program
Nov 01, 2007

OccuLogix to Release Q3-07 Financial Results on November 7-Conference Call to Follow
Oct 25, 2007

OccuLogix Board Authorizes Exploration of Strategic Alternatives to Enhance Shareholder Value
Oct 09, 2007

OccuLogix Receives Letter from Nasdaq Regarding Noncompliance with Minimum Bid Price Rule
Sep 19, 2007

OccuLogix Reports Q2-07 Financial Results
Aug 08, 2007

OccuLogix to Release Q2-07 Financial Results on August 8-Conference Call to Follow
Jul 25, 2007

OccuLogix Enters Into Discussions for Private Placement of Common Stock to Private Equity Group
Jul 03, 2007

OccuLogix Reports Q1-07 Financial Results
May 09, 2007

OccuLogix to Release Q1-07 Financial Results on May 9-Conference Call to Follow
Apr 25, 2007

OccuLogix Receives Going Concern Qualification
Mar 15, 2007

OccuLogix Reports Fourth Quarter and Full-Year 2006 Financial Results
Mar 06, 2007

OccuLogix to Present at Cowen and Company 27th Annual Health Care Conference
Feb 27, 2007

OccuLogix to Announce Fourth Quarter and Full-Year 2006 Financial Results on March 6-Conference Call to Follow
Feb 20, 2007

OccuLogix Announces US$10 Million Private Placement of Common Stock to Institutional Investors
Feb 01, 2007

OccuLogix's RHEO-AMD Trial Protocol Cleared by the FDA
Jan 29, 2007

OccuLogix Further Expands Focus on Age-Related Eye Diseases Through its Equity Investment in OcuSense
Nov 30, 2006

OccuLogix Reports Q3-06 Financial Results
Nov 01, 2006

OccuLogix to Present at CIBC World Markets 17th Annual Healthcare Conference
Oct 24, 2006

OccuLogix and Asahi Kasei Medical Sign Rheofilter'TM' SR Agreement
Oct 23, 2006

OccuLogix to Release Q3-06 Financial Results on November 1-Conference Call to Follow
Oct 17, 2006

OccuLogix Completes Acquisition of SOLX
Sep 01, 2006

OccuLogix Announces Stock Ticker Symbol Changes
Sep 01, 2006

OccuLogix Reports Q2-06 Financial Results
Aug 03, 2006

OccuLogix Enters Into Definitive Agreement to Acquire SOLX
Aug 01, 2006

OccuLogix to Release Q2-06 Financial Results on August 3-Conference Call to Follow
Jul 24, 2006

OccuLogix Terminates Negotiations with Sowood
Jun 30, 2006

OccuLogix Enters Into Letter of Intent for Proposed Private Sale of Zero-Coupon Convertible Notes
Jun 14, 2006

OccuLogix Reports On Meeting With FDA
Jun 12, 2006

OccuLogix Reports Q1-06 Financial Results
May 08, 2006

OccuLogix to Release Q1-06 Financial Results on May 8-Conference Call to Follow
May 01, 2006

OccuLogix Expands Focus on Age-Related Eye Diseases
Apr 04, 2006

OccuLogix Reports Positive MIRA-1 Analysis Results
Mar 09, 2006

OccuLogix Reports Fourth Quarter and Full-Year 2005 Financial Results
Mar 09, 2006

OccuLogix to Release Fourth Quarter & Full Year 2005 Financial Results and Provide a MIRA-1 Analysis Update on March 9-Conference Call to Follow
Mar 01, 2006

OccuLogix Provides MIRA-1 Update
Feb 03, 2006

OccuLogix Announces Acceleration of Stock Options Vesting
Dec 14, 2005

OccuLogix Establishes Scientific Advisory Board
Dec 13, 2005

All 12-Month Follow-up Visits Completed in OccuLogix's Pivotal Trial for Dry Age-Related Macular Degeneration
Nov 17, 2005

OccuLogix Achieves ISO 13485:2003 Certification
Nov 09, 2005

OccuLogix Reports Q3-05 Financial Results
Nov 07, 2005

Time Change Notice-OccuLogix Presentation at SG Cowen 6th Annual Global Healthcare Conference
Nov 04, 2005

OccuLogix Announces Upcoming Investment Community Events
Oct 20, 2005

OccuLogix, Inc.: Options Grant to Steve Parks, Vice President, Sales
Oct 14, 2005

FDA and OccuLogix Agree on Statistical Analysis & Filing Plans
Oct 11, 2005

OccuLogix, Inc.: Accomplished Industry Veteran, Steve Parks, Joins OccuLogix as Vice President of Sales
Oct 05, 2005

OccuLogix to Present at ThinkEquity Partners 3rd Annual Growth Conference
Aug 30, 2005

OccuLogix Reports Q2-05 Financial Results
Aug 04, 2005

OccuLogix to Release Q2-05 Financial Results on August 4-Conference Call to Follow
Jul 21, 2005

OccuLogix, Inc.: Positive PERC Data Presented at ASRS 2005 Annual Meeting
Jul 18, 2005

OccuLogix, Inc.: RHEO'TM' Mechanism of Action Article Published in the Canadian Journal of Ophthalmology
Jun 07, 2005

OccuLogix Appoints Veteran Life Sciences Financial Executive, John Y. Caloz, as CFO
May 19, 2005

OccuLogix Reports Q1-05 Financial Results
May 05, 2005

OccuLogix, Inc.: Positive RheoNet Registry Clinical Data Presented at ARVO 2005
May 03, 2005

OccuLogix Appoints Adrienne L. Graves, Ph.D. to Its Board of Directors
May 02, 2005

OccuLogix to Release Q1-05 Financial Results on May 5-Conference Call to Follow
Apr 21, 2005

OccuLogix Appoints Gilbert S. Omenn, M.D., Ph.D. to Its Board of Directors
Apr 18, 2005

OccuLogix to Present at the Scotia Capital Pharmaceutical & Biotechnology Conference
Apr 12, 2005

Time Change Notice-OccuLogix Presentation at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
Apr 01, 2005

OccuLogix Re-Acquires its Intellectual Property Rights to Non-Ophthalmic Indications for RHEO in North America
Mar 29, 2005

OccuLogix to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
Mar 28, 2005

OccuLogix to Present at Smith Barney Citigroup 2005 Healthcare Conference
Mar 11, 2005

OccuLogix Reports Fourth Quarter and Year End 2004 Financial Results
Mar 07, 2005

OccuLogix to Present at SG Cowen & Co. 25th Annual Health Care Conference
Mar 01, 2005

OccuLogix Receives FDA Clearance to Initiate MIRA-1 Crossover Studies
Feb 28, 2005

OccuLogix to Release Q4 and Full-year 2004 Financial Results on March 7, 2005-Conference Call to Follow
Feb 22, 2005

OccuLogix to Present at Smith Barney Citigroup 2005 Small & Mid-Cap Conference
Feb 03, 2005

OccuLogix's Pivotal Trial for Dry Age-Related Macular Degeneration Exceeds Patient Recruitment Goal
Jan 03, 2005

OccuLogix, Inc. Closes its Initial Public Offering of 8,400,000 Shares of Common Stock
Dec 16, 2004

OccuLogix, Inc. Prices Initial Public Offering of its Common Stock at US$12 Per Share
Dec 09, 2004

TLC Vision Corporation: Occulogix, Inc. Files Preliminary Prospectus in Canada in Connection With The Initial Public Offering of its Common Stock
Aug 31, 2004

OccuLogix, Inc. Files Registration Statement With The U.S. Securities And Exchange Commission For The Initial Public Offering Of Common Stock
Aug 13, 2004

TLC Vision Corporation And OccuLogix, Inc. Announce OccuLogix, Inc.'s Proposed Initial Public Offering Of Its Common Stock
Aug 09, 2004